Ƶ

Widely Used Breast Chemo Regimen Falls Short

— Taxane-cyclophosphamide regimens fail against taxane-anthracycline combinations

Ƶ MedicalToday

CHICAGO -- A widely used chemotherapy regimen for early breast cancer encountered a "practice changing failure" in a retrospective survival analysis, reported here at the American Society of Clinical Oncology meeting, involving several clinical trials. In an exclusive Ƶ video interview, , of Memorial Sloan Kettering Cancer Center in New York City, explains why breast cancer specialists might have a hard time justifying continued use of taxane-cyclophosphamide chemotherapy regimens for early breast cancer.

  • author['full_name']

    Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. He joined Ƶ in 2007.